What is Amgen Price-to-Operating-Cash-Flow?
As of today (2024-04-25), Amgen's share price is $273.01.
Amgen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $15.76. Hence, Amgen's Price-to-Operating-Cash-Flow Ratio for today is 17.32.
The historical rank and industry rank for Amgen's Price-to-Operating-Cash-Flow or its related term are showing as below:
AMGN'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.31 Med: 13.37 Max: 20.51
Current: 17.32
During the past 13 years, Amgen's highest Price-to-Operating-Cash-Flow Ratio was 20.51. The lowest was 10.31. And the median was 13.37.
Amgen's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $1.00.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $15.76.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Amgen was -12.40% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -4.00% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 0.20% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 5.80% per year.
During the past 13 years, Amgen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 239.80% per year. The lowest was -4.00% per year. And the median was 13.30% per year.
Amgen Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Amgen's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen Price-to-Operating-Cash-Flow Chart
|
Amgen Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
16.04 |
12.92 |
13.92 |
14.62 |
18.29 |
|
Amgen Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
14.62 |
15.08 |
11.05 |
13.65 |
18.29 |
Competitive Comparison of Amgen's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - General subindustry, Amgen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Amgen's Price-to-Operating-Cash-Flow falls into.
Amgen Price-to-Operating-Cash-Flow Calculation
Amgen's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 273.01 | / | 15.76 |
| = | 17.32 |
Amgen's Share Price of today is $273.01.
Amgen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.76.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Amgen (AMGN) Business Description
Traded in Other Exchanges
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Executives
| Nancy A. Grygiel |
officer: SVP & CCO |
ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320 |
| Jonathan P Graham |
officer: SVP, Gen. Counsel & Secy. |
2099 PENNSYLVANIA AVENUE, NW, 12TH FLOOR, WASHINGTON DC 20006 |
| Matthew C. Busch |
officer: VP, Finance & CAO |
ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320 |
| Murdo Gordon |
officer: EVP Global Commercial Ops |
C/O BRISTOL-MYERS SQUIBB COMPANY, 345 PARK AVE, NEW YORK NY 10154 |
| Rachna Khosla |
officer: SVP, Business Development |
ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320 |
| R Sanders Williams |
director |
DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706 |
| Robert Eckert |
director |
MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245 |
| Michael V Drake |
director |
ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320 |
| Derek Miller |
officer: SVP, Human Resources |
ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320 |
| Omar Ishrak |
director |
710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432 |
| Ronald D Sugar |
director |
10877 WILSHIRE BLVD., SUITE 1650, LOS ANGELES CA 900274 |
| Linda H. Louie |
officer: VP, Finance & CAO |
ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320 |
| Amy E Miles |
director |
|
| David Piacquad |
officer: SVP, Business Development |
ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
| Peter H. Griffith |
officer: EVP & CFO |
ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMGN has been successfully added to your